Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.54 |
| ▸ | QDPR | P09417 | 1/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698222 | 0.90 | HTR3A (0.50) | HTR2CKCNH2 | |
| SCHEMBL15247784 | 0.87 | SLC6A3 (0.43) | HTR2C | |
| SCHEMBL2708481 | 0.86 | HTR2C (0.54) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL18831900 | 0.84 | HTR2C (0.40) | HTR2CQDPRTLR9TLR8TLR7 | |
| SCHEMBL2709718 | 0.83 | HTR2C (0.59) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL12806513 | 0.83 | SLC6A3 (0.41) | — | |
| SCHEMBL1765234 | 0.83 | QDPR (0.56) | HTR2CQDPRSLC18A3SIGMAR1TNKS | |
| SCHEMBL13499937 | 0.83 | SLC6A2 (0.41) | — | |
| Hydrochloric Acid SCHEMBL4881862 | 0.81 | HTR2C (0.61) | HTR2CQDPRSLC18A3SIGMAR1TLR9 | |
| SCHEMBL11933082 | 0.81 | ACMSD (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885QDPR 214/4885SLC18A3 162/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885QDPR 214/4885SLC18A3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.